Retrospective evaluation of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer with stereotactic radiotherapy: A multi-institutional study.

Ozawa, Yuichi; Omae, Minako; Fujisawa, Masato; Kato, Masato; Asada, Kazuhiro; Sagisaka, Shinya; Karayama, Masato; Matsui, Takashi; Shirai, Toshihiro; Yasuda, Kazumasa; Nakamura, Yutaro; Inui, Naoki; Yamada, Kazunari; Yokomura, Koshi; Suda, Takafumi

doi:10.1200/jco.2014.32.15_suppl.7591

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixteen studies (20,34,35,38,39,55,56,70,(81)(82)(83)(84)(85)(86)(87)(88)) reported LS patients undergoing PCI (Figure 2C). The impact of PCI in improving survival vs patients who did not receive PCI was mixed, with some studies demonstrating an OS/progression-free survival (PFS) improvement [8 studies (20,34,35,38,39,83,85,86)], whilst others showing no improvement or a reduced OS [3 studies (82,84,88)]. However, all but one (88) studies that reported on the incidence of brain metastases found the addition of PCI led to a reduction in incidence [7 studies (20,34,35,39,81,87,89)].…”

Section: Limited Stagementioning

confidence: 99%

Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review

Johal¹,

Hettle²,

Carroll³

et al. 2021

J Thorac Dis

View full text Add to dashboard Cite

Background: Small-cell lung cancer (SCLC) accounts for 12-15% of lung cancers and is associated with poor survival outcomes and high symptom burden. This study employed a broad, systematic search strategy and timeframe to identify evidence on real-world treatment patterns and outcomes for SCLC outside the USA, including understanding sub-populations such as extensive-stage (ES) or limited-stage (LS) disease. Methods: Databases (MEDLINE, Embase, and EBM reviews) were searched for journal articles published in the English language between 1 January 2000-1 March 2020 and supplemented by hand searching of conference abstracts and posters presented at conferences between 1 January 2016-1 March 2020 reporting real-world treatment outcomes in patients with SCLC. A targeted clinical guideline review was also completed. Results: One-hundred studies provided quantitative data; 57 were available as full-text articles, whilst the remaining 43 were presented as abstracts or posters. The majority (80 studies, 80%) of included studies reported treatment in the first-line setting, where platinum-based chemotherapy and chemoradiotherapy was the most commonly used treatment strategy, in line with current treatment guidelines in SCLC. Firstline treatments were found to have a high response rate; however, most patients relapsed early. No studies reported treatment or outcomes with immune-oncology therapies. Second-line treatment options were very limited, and primarily consisted of either re-treatment with first-line regimen or topotecan, but the prognosis for these patients remained poor. Outcomes were particularly poor amongst those with ES or relapsed disease vs. LS disease. Conclusions: SCLC treatment patterns and short survival outcomes have remained constant over the previous 20 years. Due to the search timeframe, none of the studies identified reported on the impact of recently approved immune-oncology therapies in SCLC. Further data is needed on the impact of immunotherapies on treatment patterns and real-world outcomes in SCLC.

show abstract

Section: Limited Stagementioning

confidence: 99%

Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review

Johal¹,

Hettle²,

Carroll³

et al. 2021

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…Dr Yuichi Ozawa led an interesting study demonstrating that primary cranial irradiation (PCI) was unnecessary in small-cell lung cancer without visible metastases on an MRI scan [5]. This is very positive news for patients who have achieved MRI-confirmed remission of small-cell lung cancer, potentially sparing them the toxicity of prophylactic cranial irradiation.…”

Section: Lung Cancer: Small-cell Gains Groundmentioning

confidence: 99%

ecancermedicalscience

McVie

Nailor²

View full text Add to dashboard Cite

The 50th Annual Meeting of the American Society of Clinical Oncology showed a shift in the culture of cancer research, moving towards multidisciplinary, integrated, and patient-centric work. Hormone-sensitive cancers were particularly highlighted at this meeting, and impressive strides were made in the previously underserved areas of the lung and thyroid cancer. Interestingly, immunotherapy was one of the strongest themes to emerge.

show abstract

Retrospective evaluation of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer with stereotactic radiotherapy: A multi-institutional study.

Cited by 2 publications

References 0 publications

Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review

Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review

ecancermedicalscience

Contact Info

Product

Resources

About